Shares in Hims Hers Health Inc (NYSE:HIMS) fell Friday after Citigroup (NYSE:C) analysts downgraded the stock to Sell/High Risk, citing overvaluation concerns tied to its GLP-1 revenue stream. The ...

Hims & Hers Health (HIMS) stock gained after Citi upgraded the company, while agilon health (AGL) stock slipped after its downgrade. Read more here.

Citi downgraded Hims & Hers to Sell from Neutral with a price target of $25, up from $24. The firm thinks the market is overvaluing the ...

In the ‘80s, researchers set out to test a medication called sildenafil citrate for treating high blood pressure and angina (chest pain) from heart disease.

Hims offers convenient and affordable access to treatments and products tailored for men's health needs. But how much does it ...